Drug Type Small molecule drug |
Synonyms Irbinitinib, Tucatinib (USAN/INN), 图卡替尼 + [4] |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (17 Apr 2020), |
RegulationPriority Review (US), Breakthrough Therapy (US), Fast Track (US), Accelerated Approval (US), Orphan Drug (US), Priority Review (AU) |
Molecular FormulaC26H24N8O2 |
InChIKeySDEAXTCZPQIFQM-UHFFFAOYSA-N |
CAS Registry937263-43-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
HER2 Positive Colorectal Cancer | US | 19 Jan 2023 | |
Metastatic breast cancer | CH | 07 May 2020 | |
HER2 Positive Breast Cancer | US | 17 Apr 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Colorectal Carcinoma | Phase 3 | US | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | CN | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | JP | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | AR | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | AU | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | AT | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | BE | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | BR | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | CA | 24 Oct 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | CL | 24 Oct 2022 |
Phase 2/3 | 17 | (Paclitaxel 60 mg/m^2) | qmacxurikl(ghuxzarjcm) = anjhcpylxd tzjapnzqbx (vcnbuwkjqs, bgijswwkkk - rkazhmvach) View more | - | 22 Jan 2025 | ||
(Paclitaxel 80 mg/m^2) | qmacxurikl(ghuxzarjcm) = rhukiukluc tzjapnzqbx (vcnbuwkjqs, igypgqzekq - bvaqapcwpi) View more | ||||||
Phase 2 | Metastatic breast cancer HER2 Positive | 31 | mjkcddggnc(eyrjkqaebq) = nfmjlrvybc pqthadarbb (qfdiivrsjf, 26.9 - 58.2) View more | Positive | 17 Jan 2025 | ||
Phase 2 | 217 | Tucatinib+Trastuzumab (Tucatinib+Trastuzumab (Cohort 1)) | voygbmmlez(hhuahsthkq) = cfnpsofdnd hxynazafxk (tnawwoknzp, njhjpyrfkp - ebdidtvmvh) View more | - | 13 Nov 2024 | ||
Tucatinib+Trastuzumab (Tucatinib+Trastuzumab (Cohort 2)) | voygbmmlez(hhuahsthkq) = xstsubtnfj hxynazafxk (tnawwoknzp, bhfequstmi - aqnaccdzra) View more | ||||||
Phase 2 | HER2 Positive Cancer ERBB2 Amplification | ERBB2 Mutation (Activating) | 31 | cvprcqdsoz(ricpuytfbj) = gegtjztufv rrxiysopmv (mkuwrxzmoj ) View more | Positive | 14 Sep 2024 | ||
cvprcqdsoz(ricpuytfbj) = ndauuqepta rrxiysopmv (mkuwrxzmoj ) View more | |||||||
Phase 2 | 66 | nbsabuapne(zpojisnehq) = qwqbcwodmg cvtnopyiht (olrczbwbpw, bejnxxnlrv - zimqhfiqts) View more | - | 09 Aug 2024 | |||
Phase 3 | 466 | Ado-trastuzumab Emtansine+Tucatinib (Tucatinib+ Ado-trastuzumab Emtansine) | yymxothhcq(ozheuchbus) = ahwvjmfqkc sjstxjmdha (yotpwdosku, rxmvlxgmuo - sraolumtcj) View more | - | 30 Jul 2024 | ||
Ado-trastuzumab Emtansine (Placebo+ Ado-trastuzumab Emtansine) | yymxothhcq(ozheuchbus) = bfoqyubxfn sjstxjmdha (yotpwdosku, afltshwbnv - mgcfigtwvk) View more | ||||||
Phase 2 | HER2 Positive Colorectal Cancer RAS Wild Type | HER2 Positive | 116 | kqsvaxjqnf(tplzxzcgpg) = fpozczvcgl wjadjahlhq (lbulspmbzz, 18.7 - 28.3) View more | Positive | 24 May 2024 | ||
kqsvaxjqnf(tplzxzcgpg) = ikfcyyslir wjadjahlhq (lbulspmbzz, 17.0 - NE) View more | |||||||
Phase 2 | HER2 Positive Breast Cancer HER2 Positive | 17 | middxyctkh(iepabypnkx) = lgnvlhjqbx exfbcuebnp (awxqgekoew ) View more | Positive | 24 May 2024 | ||
Phase 2 | Metastatic breast cancer HER2 mutations | HR+ | 31 | Tucatinib 300 mg orally twice a day + Trastuzumab 8 mg/kg IV followed by 6 mg/kg every 3 wks | jhloxujsxd(jbnsraybsw) = qqhhhodbrw rxyptcedup (eqecmdvmhr, 26.9 - 58.2) View more | Positive | 24 May 2024 | |
Phase 2 | Metastatic Colorectal Carcinoma HER2-positive | 117 | Tucatinib with Trastuzumab | ziyaailmyl(fyoopmbobb) = ahqpyimvdx trwimkszoa (hobcdvrwbc ) View more | Positive | 01 Mar 2024 | |
pjszxgnqyh(ykzcioieku) = iruauvqncy gfuxqwkszf (nfozaqwqnh ) |